AI-generated analysis. Always verify with the original filing.
IceCure Medical Ltd is a commercial-stage medical device company developing cryoablation systems for tumor treatment, with ProSense FDA-approved for low-risk breast cancer in women 70+. This F-1 registers resale of up to 16M ordinary shares by selling shareholders from the March 2026 offering, with company receiving proceeds only from warrant exercises for working capital.
IceCure Medical Ltd operates as a commercial-stage medical device company specializing in cryoablation technology using liquid nitrogen to destroy benign and malignant tumors, positioning ProSense as a minimally invasive alternative to surgery for breast, lung, kidney, bone, and other indications. The lead product, ProSense system with CryoProbes, holds FDA marketing authorization specifically for local treatment of low-risk breast cancer with adjuvant endocrine therapy in women aged 70 and above, including those unsuitable for surgery, marking a key regulatory milestone that enables commercial activity in the U.S. market. As an Israeli corporation listed on Nasdaq Capital Market under ICCM since 2021 and previously on Tel Aviv Stock Exchange, the company benefits from foreign private issuer status, allowing reduced SEC reporting frequency compared to U.S. domestics, alongside emerging growth company exemptions under the JOBS Act.
The F-1 registration facilitates resale by selling shareholders of up to 16,000,000 Ordinary Shares underlying Series B and Series C Warrants issued in the March 26, 2026 registered direct offering and private placement, where investors purchased 8M shares at $0.50 each for $4M gross proceeds (net ~$3.5M after 7% placement agent fee to A.G.P.). Warrants, exercisable immediately at $0.55/share, expire in 5 years (Series B) or 1 year (Series C), potentially yielding $8.8M more to IceCure upon full exercise for working capital and general purposes. Company receives no proceeds from share resales, which could pressure the $0.30 share price (March 31, 2026 close) given low historical volume and limited float. With 81.2M shares outstanding as of March 31, 2026, this resale represents 19.7%, and full exercise of these plus prior warrants (Rights Offering, etc.) could expand shares to 106.9M, diluting ownership by 31.7% and risking further price declines.
Financial snapshot as of December 31, 2025 shows $8.9M cash equivalents and $9.1M shareholders' equity amid $120.4M accumulated losses, reflecting R&D burn typical for medtech without disclosed revenue trajectory. Pro forma post-March offering cash rises to $12.4M, $21.2M if warrants fully exercised. Equity overhang includes 4.2M options, 1.9M RSUs, and 9.7M Rights Offering warrants, amplifying dilution risks without preemptive rights. Governance features a classified board (5-11 directors), no dual-class, and Israeli Companies Law protections like special tender offers for control changes.
Core risks center on dilution from ongoing financings (effective F-3 shelf with $96M remaining), Nasdaq delisting threats, regulatory hurdles for new indications/post-market studies, and enforcement difficulties for U.S. investors given Israeli base and directors in China/Hong Kong. No dividends planned, with returns solely from appreciation amid volatile biotech trading. Placement by A.G.P. underscores institutional interest from funds like Armistice (10.7M shares beneficially) despite 4.99% warrant caps. Investors face high risk in this sub-$0.50/share name with working capital needs, but upside from cryoablation adoption in underserved tumor segments.
Offering Amount
$4.8M
Shares Offered
2,500,000,000
Price Range
$0.74 – $1.22
Issuer Type
Shares Offered
16,000,000
Share Type
Ordinary Shares
Exchange
Nasdaq Capital Market
Ticker
ICCM
Use of Proceeds: No proceeds from sale of Ordinary Shares by selling shareholders; proceeds from exercise of Warrants for working capital and other general corporate purposes.
Commercial stage medical device company focusing on research, development and marketing of cryoablation systems and technologies based on liquid nitrogen for treating tumors including breast, lungs, kidneys, bones.